HK1009045A1 - Palladium catalyzed ring closure of triazolyl tryptamine - Google Patents

Palladium catalyzed ring closure of triazolyl tryptamine

Info

Publication number
HK1009045A1
HK1009045A1 HK98109812A HK98109812A HK1009045A1 HK 1009045 A1 HK1009045 A1 HK 1009045A1 HK 98109812 A HK98109812 A HK 98109812A HK 98109812 A HK98109812 A HK 98109812A HK 1009045 A1 HK1009045 A1 HK 1009045A1
Authority
HK
Hong Kong
Prior art keywords
ring closure
tryptamine
triazolyl
catalyzed ring
palladium catalyzed
Prior art date
Application number
HK98109812A
Other languages
English (en)
Inventor
Cheng Y Chen
Robert D Larsen
Thomas R Verhoeven
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of HK1009045A1 publication Critical patent/HK1009045A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Inorganic Insulating Materials (AREA)
HK98109812A 1994-05-24 1998-08-11 Palladium catalyzed ring closure of triazolyl tryptamine HK1009045A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/248,288 US5567824A (en) 1994-05-24 1994-05-24 Palladium catalyzed ring closure of triazolyltryptamine
PCT/US1995/005506 WO1995032197A1 (en) 1994-05-24 1995-05-19 Palladium catalyzed ring closure of triazolyl tryptamine

Publications (1)

Publication Number Publication Date
HK1009045A1 true HK1009045A1 (en) 1999-05-21

Family

ID=22938473

Family Applications (2)

Application Number Title Priority Date Filing Date
HK98109812A HK1009045A1 (en) 1994-05-24 1998-08-11 Palladium catalyzed ring closure of triazolyl tryptamine
HK02102830.8A HK1041262B (zh) 1994-05-24 2002-04-15 吲衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK02102830.8A HK1041262B (zh) 1994-05-24 2002-04-15 吲衍生物

Country Status (24)

Country Link
US (1) US5567824A (ja)
EP (1) EP0763032B1 (ja)
JP (1) JP3947216B2 (ja)
KR (1) KR100385027B1 (ja)
CN (2) CN1157390C (ja)
AT (1) ATE252095T1 (ja)
AU (1) AU688505B2 (ja)
DE (1) DE69531939T2 (ja)
DK (1) DK0763032T3 (ja)
ES (1) ES2207648T3 (ja)
FI (1) FI116899B (ja)
HK (2) HK1009045A1 (ja)
HR (1) HRP950304B1 (ja)
HU (1) HU226460B1 (ja)
MX (1) MX9605838A (ja)
NZ (1) NZ285539A (ja)
PT (1) PT763032E (ja)
RO (1) RO118586B1 (ja)
RU (1) RU2138496C1 (ja)
SK (1) SK284495B6 (ja)
TW (1) TW300221B (ja)
UA (1) UA52586C2 (ja)
WO (1) WO1995032197A1 (ja)
YU (1) YU49345B (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA965837B (en) * 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
DE69616335T2 (de) * 1995-07-11 2002-07-11 Merck & Co Inc Ein triazolylmethyl-indol-ethylamin-bisulfat-salz
US5811551A (en) * 1996-08-13 1998-09-22 Merck & Co., Inc. Palladium catalyzed indolization
US5808064A (en) * 1996-08-13 1998-09-15 Merck & Co., Inc. Palladium catalyzed indolization
US5877329A (en) * 1996-08-13 1999-03-02 Merck & Co., Inc. Palladium catalyzed indolization
ATE228137T1 (de) * 1996-08-13 2002-12-15 Merck & Co Inc Palladiumkatalysierte indolisierung
DE60033859T2 (de) * 1999-06-28 2007-11-08 Janssen Pharmaceutica N.V. Hemmer des Respiratorischen Syncytial Virus
ES2204303B2 (es) * 2002-08-07 2004-12-16 Laboratorios Vita, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo.
US7777049B2 (en) * 2004-01-09 2010-08-17 Ratiopharm Gmbh Crystalline forms of Rizatriptan benzoate
ATE461916T1 (de) * 2004-01-28 2010-04-15 Ratiopharm Gmbh Syntheseverfahren und zwischenprodukte zur herstellung von rizatriptan
GT200500065A (es) * 2004-03-26 2005-10-24 Procedimientos para la preparacion de compuestos aminoarilos yodados
WO2006082598A2 (en) * 2005-02-01 2006-08-10 Natco Pharma Limited Novel crystalline forms of rizatriptan benzoate
WO2006137083A1 (en) * 2005-06-20 2006-12-28 Natco Pharma Limited Improved process for the preparation of rizatriptan benzoate
US20090062550A1 (en) * 2005-11-14 2009-03-05 Matrix Laboratories Ltd Process for the Large Scale Production of Rizatriptan Benzoate
WO2007083320A2 (en) * 2006-01-19 2007-07-26 Matrix Laboratories Ltd Conversion of aromatic diazonium salt to aryl hydrazine
WO2008149152A1 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Novel process
EP3407869A1 (en) 2016-01-27 2018-12-05 Instar Technologies A.S. Oromucosal nanofiber carriers for therapeutic treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
CA2084531A1 (en) * 1991-12-19 1993-06-20 David W. Smith Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines
GB9215526D0 (en) * 1992-07-22 1992-09-02 Merck Sharp & Dohme Chemical process

Also Published As

Publication number Publication date
AU688505B2 (en) 1998-03-12
EP0763032A1 (en) 1997-03-19
ATE252095T1 (de) 2003-11-15
DE69531939T2 (de) 2004-07-29
DE69531939D1 (de) 2003-11-20
CN1077104C (zh) 2002-01-02
HRP950304A2 (en) 1997-08-31
HU226460B1 (en) 2008-12-29
KR970703336A (ko) 1997-07-03
RO118586B1 (ro) 2003-07-30
RU2138496C1 (ru) 1999-09-27
UA52586C2 (uk) 2003-01-15
US5567824A (en) 1996-10-22
FI964669A0 (fi) 1996-11-22
CN1322725A (zh) 2001-11-21
CN1152920A (zh) 1997-06-25
ES2207648T3 (es) 2004-06-01
CN1157390C (zh) 2004-07-14
PT763032E (pt) 2004-02-27
FI964669A (fi) 1996-11-22
JP3947216B2 (ja) 2007-07-18
YU49345B (sh) 2005-07-19
HK1041262A1 (en) 2002-07-05
YU33495A (sh) 1998-07-10
FI116899B (fi) 2006-03-31
NZ285539A (en) 1998-06-26
AU2467195A (en) 1995-12-18
KR100385027B1 (ko) 2003-08-14
DK0763032T3 (da) 2004-02-09
HK1041262B (zh) 2005-04-15
HRP950304B1 (en) 2004-12-31
HU9603236D0 (en) 1997-01-28
TW300221B (ja) 1997-03-11
EP0763032B1 (en) 2003-10-15
JPH10500680A (ja) 1998-01-20
SK149896A3 (en) 1997-09-10
HUT76469A (en) 1997-09-29
SK284495B6 (sk) 2005-05-05
WO1995032197A1 (en) 1995-11-30
MX9605838A (es) 1997-12-31

Similar Documents

Publication Publication Date Title
HK1009045A1 (en) Palladium catalyzed ring closure of triazolyl tryptamine
EA200000393A1 (ru) Химические соединения
PT74626A (en) Process for preparing 9-<2-(3-indolyl)ethyl>-1-oxa-4,9-diazas- piro<5,5>undecan-3-ones
GB9412590D0 (en) Organic compounds
ATE48835T1 (de) Chinolylglycinamidderivate, verfahren zu ihrer herstellung und therapeutische verwendung als psychotrope.
GB9004301D0 (en) Indolebutyric acid derivatives and process for preparation thereof
YU217181A (en) Process for preparing 2-(1,4-benzodioxane-2-ylalkyl)-imidazoles
NO178030C (no) Analogifremgangsmåte ved fremstilling av terapeutisk aktive metylenbisfosfonsyrederivater
KR840004746A (ko) 2-옥소-1-아제티딘술폰산 유도체의 제조방법
GB9306899D0 (en) Substituted (arylalkylaminobenzyl) aminopropionamide derivatives and process for their preparation
CA2190851A1 (en) Palladium catalyzed ring closure of triazolyl tryptamine
JPS5359663A (en) 2-halogeno methyl indole derivatives and process for praparation of the same
HU912559D0 (en) Process for producing 4-amino-delta-4'6-steroids
ES2160909T3 (es) Procedimiento para la preparacion de 4-amino-1,2,4-triazoles.
GR3032427T3 (en) An improved process for preparing side chain derivatives of cyclohexapeptidyl lipopeptides
ES8407042A1 (es) Procedimiento para la obtencion de un nuevo derivado del sulpiride.
HU9302786D0 (en) New thiophene-2-carboxylic acid derivatives and process for preparing them
KR970042548A (ko) 이미다조 피리딘 유도체,이의 제조방법 및 이를 함유한 약제학적 조성물
GB9815481D0 (en) Pharmaceuticals
JPS5681559A (en) Novel hydrazone compound and its preparation
HUP0000144A2 (hu) Eljárás hidroxi-heteroaromás vegyületek aril-aminokká való átalakítására
RO116269B1 (ro) Procedeu de obţinere a silicatului de sodiu lichid
JPS5640677A (en) Catechol derivative and its preparation
JPS5566562A (en) Novel imidazole derivative and antidepressant containing the same

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20150518